Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.

Détails

ID Serval
serval:BIB_EEF4B976E6D4
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Périodique
Multiple sclerosis
Auteur(s)
Bacchetta F., Mathias A., Schluep M., Du Pasquier R.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Statut éditorial
Publié
Date de publication
02/2017
Peer-reviewed
Oui
Volume
23
Numéro
2
Pages
300-303
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
Natalizumab, a treatment used in multiple sclerosis (MS), is associated with cases of progressive multifocal leukoencephalopathy (PML).
We describe two cases of PML in related but not genetically apparented natalizumab-treated MS patients who are stepsisters. Reported cases/outcomes: While Patient 1 developed PML, Patient 2 was on natalizumab and had contacts with Patient 1. Patient 2 was diagnosed with PML 5 months after Patient 1.
The clinical and temporal data highly suggest that there was JC virus (JCV) transmission from one patient to the other with development of PML as primo-infection in Patient 2.

Mots-clé
Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Viral/immunology, Brain/pathology, Female, Humans, JC Virus/immunology, JC Virus/pathogenicity, Leukoencephalopathy, Progressive Multifocal/diagnosis, Leukoencephalopathy, Progressive Multifocal/etiology, Leukoencephalopathy, Progressive Multifocal/pathology, Middle Aged, Multiple Sclerosis/complications, Multiple Sclerosis/drug therapy, Natalizumab/adverse effects, Natalizumab/therapeutic use, JC virus, Natalizumab, multiple sclerosis, progressive multifocal leukoencephalopathy, transmission
Pubmed
Web of science
Création de la notice
14/02/2017 12:00
Dernière modification de la notice
15/03/2018 21:48
Données d'usage